Literature DB >> 1575183

Usefulness of single-photon emission computed tomography of thallium-201 uptake after dipyridamole infusion for detection of coronary artery disease.

M A Mendelson1, S M Spies, W G Spies, P Abi-Mansour, D J Fintel.   

Abstract

The diagnostic performance of single-photon emission computed tomography (SPECT) and planar imaging of thallium-201 uptake for the detection of coronary artery disease (CAD) was compared in 79 patients who underwent both dipyridamole thallium-201 scintigraphy and coronary angiography. Clinical subgroups were assigned by severity of CAD, presence of a prior myocardial infarction and the number of narrowed coronary arteries. The overall detection of CAD was 89% for SPECT and 67% for planar (p less than 0.001). For the anterior vascular territory, sensitivities for SPECT and planar imaging were 69 and 44% (p less than 0.01), respectively; for the posterior vascular territory, sensitivities were 80 and 54% (p less than 0.01). Receiver-operating characteristic analysis, using a 5-point evaluation scale, was performed for the anterior and posterior vascular territories. Receiver-operating characteristic curves generated for SPECT and planar studies demonstrated improved diagnostic performance by SPECT in the anterior vascular territory, but showed similar performance in the posterior territory because of lower SPECT specificity despite higher sensitivity at clinically relevant decision thresholds. In each clinical subgroup of patients, the detection of CAD by SPECT was significantly superior to that by planar imaging, regardless of the severity of stenosis or the number of significantly narrowed coronary arteries, or whether a myocardial infarction was present. Thus, SPECT thallium-201 scintigraphy is an important and necessary clinical tool for detecting CAD after dipyridamole infusion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1575183     DOI: 10.1016/0002-9149(92)90927-q

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Diagnostic accuracy of dipyridamole technetium 99m-labeled sestamibi myocardial tomography for detection of coronary artery disease.

Authors:  D D Miller; L T Younis; B R Chaitman; H Stratmann
Journal:  J Nucl Cardiol       Date:  1997 Jan-Feb       Impact factor: 5.952

Review 2.  Diagnosis of coronary artery disease by radionuclide myocardial perfusion imaging.

Authors:  C Y Loong; C Anagnostopoulos
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

3.  Experience of low-dose aminophylline use to relieve minor adverse effects of dipyridamole in patients undergoing stress myocardial perfusion imaging.

Authors:  Li-Fan Lin; Cheng-Yi Cheng; Cheng-Han Hou; Chih-Hung Ku; Neng-Chuan Tseng; Daniel H Y Shen
Journal:  J Nucl Cardiol       Date:  2014-03-14       Impact factor: 5.952

4.  Comparison of planar imaging and single-photon emission computed tomography for the detection and localization of coronary artery disease.

Authors:  J P Hacot; M Bojovic; J Delonca; B Meier; A Righetti
Journal:  Int J Card Imaging       Date:  1993-06

5.  Influence of chronic renal failure on the heart rate response to dipyridamole in patients undergoing myocardial perfusion SPECT.

Authors:  Andrea De Lorenzo; Ronaldo S L Lima
Journal:  J Nucl Cardiol       Date:  2008-03-06       Impact factor: 3.872

Review 6.  Myocardial perfusion scintigraphy: the evidence.

Authors:  S R Underwood; C Anagnostopoulos; M Cerqueira; P J Ell; E J Flint; M Harbinson; A D Kelion; A Al-Mohammad; E M Prvulovich; L J Shaw; A C Tweddel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.